Kalaris Therapeutics, Inc. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Kalaris Therapeutics filed an 8-K on July 6, 2026 (reporting event of July 3, 2026) disclosing Item 5.02 matters concerning departure of directors or officers and changes to compensatory arrangements. The filing text provided does not include the specific details of which officers departed, their titles, compensation amounts, equity grants, or other material terms of any arrangements.
Why this rating
Officer transitions are routine for small public companies; lack of disclosed specifics prevents materiality assessment. Cannot quantify impact without actual compensation figures or officer identity.
Extracted items
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.